Crescent Biopharma (NASDAQ:CBIO) Upgraded to Hold at Wall Street Zen

Crescent Biopharma (NASDAQ:CBIO) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

Several other analysts have also issued reports on the stock. Stifel Nicolaus set a $29.00 target price on shares of Crescent Biopharma in a research note on Thursday, February 26th. Guggenheim assumed coverage on Crescent Biopharma in a research note on Wednesday, January 21st. They issued a “buy” rating and a $35.00 price objective on the stock. Piper Sandler initiated coverage on Crescent Biopharma in a report on Wednesday, January 28th. They set an “overweight” rating and a $35.00 price objective for the company. Weiss Ratings reaffirmed a “sell (e-)” rating on shares of Crescent Biopharma in a report on Monday, December 29th. Finally, HC Wainwright lowered their price objective on Crescent Biopharma from $25.00 to $22.00 and set a “buy” rating on the stock in a research report on Monday, March 2nd. Three investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $28.00.

Crescent Biopharma Stock Performance

CBIO stock opened at $12.07 on Friday. The business has a 50-day simple moving average of $11.19 and a two-hundred day simple moving average of $12.35. The company has a market capitalization of $167.65 million, a P/E ratio of -0.85 and a beta of 1.31. Crescent Biopharma has a 52-week low of $8.72 and a 52-week high of $28.77.

Crescent Biopharma (NASDAQ:CBIO) last issued its quarterly earnings data on Thursday, February 26th. The biopharmaceutical company reported ($4.01) EPS for the quarter, missing the consensus estimate of ($2.22) by ($1.79). The firm had revenue of $10.84 million during the quarter. As a group, sell-side analysts forecast that Crescent Biopharma will post -0.16 earnings per share for the current fiscal year.

Institutional Trading of Crescent Biopharma

Institutional investors have recently added to or reduced their stakes in the business. Fcpm Iii Services B.V. purchased a new position in shares of Crescent Biopharma in the 4th quarter worth $19,899,000. Vestal Point Capital LP bought a new position in shares of Crescent Biopharma during the 4th quarter valued at approximately $17,790,000. BVF Inc. IL purchased a new stake in Crescent Biopharma in the 2nd quarter worth approximately $22,400,000. Opaleye Management Inc. purchased a new stake in Crescent Biopharma in the 4th quarter worth approximately $13,975,000. Finally, Vanguard Group Inc. bought a new stake in Crescent Biopharma during the 3rd quarter worth approximately $7,822,000. 75.19% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Crescent Biopharma

Here are the key news stories impacting Crescent Biopharma this week:

• Positive Sentiment: HC Wainwright raised near‑term EPS forecasts across Q1–Q4 2026 and materially cut its FY2026 loss estimate while keeping a “Buy” rating and a $22 target — a clear catalyst for bullish sentiment and price support. HC Wainwright Note
• Positive Sentiment: The company’s strategic R&D alliance (reported earlier) to expand combination and bispecific ADC ambitions with Kelun‑Biotech supports future pipeline value and upside potential if clinical progress continues. Crescent‑Kelun Alliance
• Neutral Sentiment: Crescent disclosed inducement stock option grants (45,675 shares aggregate) to two non‑executive hires under its inducement plan; a routine hiring incentive that creates modest potential dilution but is primarily operational/administrative. Inducement Awards
• Neutral Sentiment: Reported short‑interest posts appear to show zero shares short and nonsensical “NaN” changes — the data is inconsistent. If accurate, extremely low short interest reduces immediate downward pressure, but the reporting anomalies make the impact uncertain.

About Crescent Biopharma

Crescent Biopharma, Inc (NASDAQ: CBIO) is a clinical‐stage immuno‐oncology company focused on the discovery, development and commercialization of novel therapies for patients with solid tumors. The company’s research strategy centers on combination approaches that enhance anti‐tumor immune responses by simultaneously targeting multiple pathways implicated in immune evasion and tumor growth.

The company’s lead candidate, CPB-201, is a bifunctional fusion protein designed to block programmed death-ligand 1 (PD-L1) while neutralizing transforming growth factor-beta (TGF-β), with the goal of restoring T-cell activity and reducing tumor fibrosis.